Ticker LaunchReverse merger · Completed · PVLA
Palvella Therapeutics, Inc.
Reverse merger with Pieris Pharmaceuticals, Inc.
Palvella Therapeutics, Inc. merged into Pieris Pharmaceuticals, Inc., a Nasdaq-listed clinical-stage biotech, in a reverse merger that takes the private company public. The deal was announced on Jul 24, 2024 and closed on Dec 13, 2024. The combined company trades as Palvella Therapeutics, Inc. (PVLA) on Nasdaq.
Palvella Therapeutics is a late clinical-stage rare disease biopharmaceutical company developing QTORIN rapamycin, a 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations and cutaneous venous malformations, among other serious genetic skin diseases.
- Status
- Completed
- Private company
- Palvella Therapeutics, Inc.
- Public company
- Pieris Pharmaceuticals, Inc.
- Public company business before
- Nasdaq-listed clinical-stage biotech
- Announced
- Jul 24, 2024
- Closed
- Dec 13, 2024
- Combined company
- Palvella Therapeutics, Inc. (PVLA)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Concurrent financing and investors
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Announcement press release
- Closing 8-K Dec 16, 2024
- Closing press release
- All filings on EDGAR CIK 1583648
Other completed reverse mergers
- Adaptin Bio, Inc.into Unite Acquisition 1 Corp. · Feb 11, 2025
- First Person Ltd.into Qrons Inc. · Jan 27, 2025
- Xinghe Technology Limitedinto Jingbo Technology, Inc. · Dec 12, 2024
- Lomond Therapeutics, Inc.into Venetian-1 Acquisition Corp. · Nov 1, 2024
- TuHURA Biosciences, Inc.into Kintara Therapeutics, Inc. · Oct 18, 2024
- NAYA Biosciences, Inc.into INVO Bioscience, Inc. · Oct 11, 2024